Sanofi Inc.

Summary: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)  Xenpozyme is the first approved medication to treat symptoms that are not related…

Summary : Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and significantly reduced…

Synopsis : Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in…

Summary : Two-year data shows Pompe disease patients treated with Nexviazyme® (avalglucosidase alfa) have sustained improvements in respiratory function and mobility. Sanofi has…

Summary : Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria In this Phase 3 trial, Dupixent…

Synopsis : Pharma giants take major stride as vaccine shows significant increase in neutralising antibodies Sanofi and GlaxoSmithKline (GSK) have announced that…

Summary : Sanofi announced the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising pipeline of T-cell engagers and cytokine…

Synopsis : Sanofi has been a global healthcare leader that has brought forth treatments for rare diseases and established standard-of-care therapeutics for…

Synopsis : Sanofi and Exscientia announced a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates…

Summary – A new drug recently introduced for use in the treatment of refractory/relapsed multiple myeloma looks like it will also find…